Gistinfo

Latest Research

GCRF is grateful for the assistance of members of our medical advisory board. This page is their forum to communicate to you late-breaking news, important links, white papers, or simply opinions that are of interest to those involved with GIST.

 

April 2013:

• Gastrointestinal Cancer Advances: News from the 2013 Gastrointestinal Cancers Symposium

   

November 2012:

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

• Regorafenib Prolongs Progression-Free Survival in Imatinib- and Sunitinib-Resistant GIST

August 2012:

• Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene - This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST

July 2012:

• Researchers Discover Imatinib’s Effect Is Due Partly to Immune System  
  Memorial Sloan-Kettering researchers have made a surprising discovery about imatinib’s mode of action against GIST: The drug appears to work partly by stimulating the immune system to attack the cancer. 

June 2012:

• Bayer's Drug Meets Chief Goals In Late-Stage Study Of Patients With GIST
  RTT News
  The study enrolled 199 patients with metastatic and/or unresectable gastrointestinal stromal tumors, or GIST – an aggressive form of stomach tumor. These patients' disease had progressed despite prior treatment with imatinib and sunitinib – the …
  See all stories on this topic »
• Studies Show Bayer, Boehringer Ingelheim Drugs Slow GIST, Lung-Cancer Growth
  Fox Business
  The study looking at regorafenib in GIST involved 199 patients who had been previously treated with Novartis AG's (NVS, NOVN.VX) Gleevec or Pfizer Inc.'s (PFE) Sutent. The patients tumors had become resistant to Gleevec and Sutent, …
  See all stories on this topic »
• Phase III Data on Bayer's Regorafenib Met Primary Endpoint Showing Significant …
  MarketWatch (press release)
  WAYNE, NJ, June 4, 2012 /PRNewswire via COMTEX/ — Bayer HealthCare today announced data from the Phase III GRID (GIST – Regorafenib In Progressive Disease) trial evaluating its investigational drug regorafenib in patients with metastatic and/or …
  See all stories on this topic »
• Phase 3 Data on Regorafenib Met Primary Endpoint Showing Significant …
  MarketWatch (press release)
  SOUTH SAN FRANCISCO, Calif., June 4, 2012 /PRNewswire via COMTEX/ — Onyx Pharmaceuticals (NASDAQ:ONXX) today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, …
  See all stories on this topic »

  Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST OncLive Imatinib (Gleevec, Novartis) and sunitinib (Sutent, Pfizer) are the only FDA-approved therapies for GIST; however, 90% of patients eventually become resistant to these treatments. Regorafenib's unique shape allows the drug to inhibit the KIT and PDGFR … See all stories on this topic »

  OncLive

  ASCO: Bayer's Novel Drug Boosts Survival in Rare GI Cancer
  MedPage Today
  The novel kinase inhibitor regorafenib substantially reduces relapse risk from treatment-refractory gastrointestinal stromal tumors (GIST). Although overall survival was statistically similar between groups as expected due to a trial design that …
  See all stories on this topic »

• Bayer says drug shows promise vs. gastrointestinal cancer
  Reuters
  The 199-patient late-stage trial showed the drug prolonged the lives of patients with metastatic gastrointestinal stromal tumors, or GIST, by almost four months on average without a worsening of their condition, Bayer said. The median survival period …
  See all stories on this topic »

  Onyx Pharmaceuticals reports phase 3 trial results for cancer drug meet main goal Proactive Investors USA & Canada Onyx Pharmaceuticals (NASDAQ:ONXX) said Monday that its investigational drug regorafenib met the main goal of a phase 3 trial, showing significant improvement in progression-free survival in patients with gastrointestinal stromal tumors (GIST). See all stories on this topic »

  Proactive Investors USA & Canada

• Bayer's Regorafenib Met Primary PFS Endpoint in Late-Stage GIST Trial
  Genetic Engineering News
  Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, …
  See all stories on this topic »
• Onyx Pharma: Regorafenib Met Primary Goal In Phase 3 Trial
  RTT News
  (RTTNews) – Onyx Pharmaceuticals (ONXX: News ) Monday revealed positive results from a late-stage study with regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors or GIST, whose disease had progressed despite prior …
  See all stories on this topic »

May 2012:

• The War on GIST: Life, Death, and Everything In Between - GCRF Research Update 2012 (Michael Heinrich, M.D.)
• GIST Research Updates: May 2012, Heinrich & Corless Laboratories

• Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST)

• Imatinib plasma levels: correlation with clinical benefit in GIST patients

• Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing

• The role of imatinib plasma level testing in gastrointestinal stromal tumor

September 2011:

• Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

November 2010:

• Update on SUTENT

October 2010:

• Info on GLEEVEC (imatinib mesylate) tablets for oral use
• Cooperative Genes Trigger Cancer (Nature)
  

August 2010:

• The Researcher Perspective: Delivering Hope with Gloved Hands
• Systemic Therapy for Metastatic GIST (pdf presentation)

July 2010:

• Update on SUTENT from Pfizer

May 2010:

• New GIST recurrence prediction tool unveiled

April 2010:

• Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells (pdf file)

• Update from Duensing Lab

March 2010:

Update in GIST Research Antonescu’ Lab, MSKCC

GIST research in the DeMatteo Laboratory

Update in GIST Research Antonescu’ Lab, MSKCC

1. IGF1R targeting in pediatric and wild-type GIST

2. Drug testing in short-term culture of WT GIST, using KIT and downstream targets inhibitors.

3. SDH screening in pediatric and Wild-type GIST (collaborative effort with Su Kim and Constantine Stratakis, from NIH), including MSKCC samples as well as NIH pediatric clinic cases

January 2010:

White Paper:  PATHOGENESIS AND MOLECULARLY TARGETED THERAPY OF GASTROINTESTINAL STROMAL TUMORS (GISTS)

Andrew Godwin, Ph.D. Fox Chase Cancer Center: Link Member, Medical Science Division GIST Research: Genetic Susceptibility to Cancer and Molecular-Targeted Therapies (pdf) Additional information on GIST Research: Click here to download PATHOGENESIS AND MOLECULARLY TARGETED THERAPY OF GASTROINTESTINAL STROMAL TUMORS (GISTS)	Anette Duensing, M.D. University of Pittsburgh Cancer Institute: Link Research Assistant Professor of Pathology Read more from Anette Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells Duensing Lab	Cristina Antonescu, M.D. Memorial Sloan Kettering Cancer Center: Link Physician, Anatomical Pathology GIST Research: Soft Tissue Sarcoma, GIST Read more from Cristina Update in GIST Research March, 2010 Update in GIST Research February, 2010	Christopher L. Corless, M.D., Ph.D. Oregon Health & Science University: Professor of Medicine, Anatomic Pathology GIST Research: Gastrointestinal Pathology, Molecular Testing Read more from Christopher
Margaret von Mehren, M.D. Fox Chase Cancer Center: Link Director, Sarcoma Oncology – GIST Research: Sarcoma Program – Research Studies (pdf) Read more from Margaret	Ronald DeMatteo, M.D. Memorial Sloan Kettering Cancer Center: Link Physician GIST Research: Soft Tissue Sarcoma, GIST GIST research in the DeMatteo Laboratory	Michael C. Heinrich, M.D. Michael Heinrich M.D. is currently a Professor of Medicine at Oregon Health & Sciences University. He earned his medical degree in 1984 from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and Hematology and Medical Oncology fellowship at OHSU.	George D. Demetri, M.D Dana Farber Cancer Institute: Link Director, Center for Sarcoma and Bone Oncology Associate Professor of Medicine, Harvard Medical School GIST Research: Sarcoma and Bone Oncology, Sarcoma.net Abstracts by Dr. Demetri, M.D.
Jonathan A. Fletcher, M.D. Dana Farber Cancer Institute: Link Physician, Cytogenetics	Katherine ("Katie") Janeway, M.D. Katie is an attending physician in Pediatric Hematology-Oncology at Children’s Hospital and Dana Farber Cancer Institute and a Harvard Medical School Instructor of Pediatrics. She splits her time between pediatric oncology clinical care and research. Read More…